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Options for the prevention of hereditary breast and ovarian cancer include screening, preventive surgery and
chemoprevention. Screening studies with magnetic resonance imaging of the breast are promising but the
technology is not widespread and MRI is unlikely to be available as a screening tool in the near future. Prophylactic
oophorectomy and mastectomy are effective preventive measures and are gaining in acceptance by patients
and physicians. Preventive mastectomy is effective against both primary and contralateral breast cancer.
Oophorectomy prevents ovarian cancer, and if done prior to menopause, will prevent breast cancer as well.
Tamoxifen has been shown to prevent contralateral breast cancers in BRCA1 and BRCA2 carriers but is not
widely accepted as a means of primary prevention. Oral contraceptives and tubal ligation will reduce the risk
of hereditary ovarian cancer and should be considered in women who wish to retain ovarian function. 
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It is nearly ten years since the BRCA1 gene was
identified and genetic testing for breast cancer
susceptibility is now widespread. During the last ten
years we have come to accept that genetic testing
can be done outside of research settings, that most
women  wish  to  have  –  and  are  capable  of
understanding – personal information about the risks
and benefits of genetic testing and that routine
pre-test psychological counselling is not mandatory.
As a group, women do not suffer unduly from anxiety
or depression following the receipt of a positive test
result [1] (although we all know of exceptions to this
rule). There is still uncertainty about the best estimate
to give a carrier for her risks of breast and ovarian
cancer. Some argue that different carriers should be
given different risks depending on their family history,
but this individualized approach to counselling is
really too complicated to be practical. But we all
agree that the risks are unacceptably high and that
something needs to be done to lower them. 
It was a relatively straightforward task to establish
that prophylactic mastectomy is effective. This has been
shown in a small prospective study [2], and in historical
cohort studies of primary [3] and contralateral [4] breast
cancers. Here the data is consistent. Meijers-Heijboer
and colleagues observed no case of breast cancer
among  76  women  who  underwent  prophylactic
mastectomy after a mean follow-up of three years [2].
Metcalfe and colleagues studied 491 women treated
for hereditary breast cancer [4]. Only one contralateral
breast cancer was observed among 146 women who
had undergone a contralateral mastectomy, versus 42
expected (p<0.0001). Some debate remains about the
optimal age of prophylactic mastectomy and about the
best techniques for mastectomy and for reconstruction,H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 6
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but  there  are  few  who  would  argue  against  the
effectiveness of the procedure. But our aim is to replace
prophylactic mastectomy with something better. This will
either come from screening or from finding a less
invasive means of primary prevention. 
The goal of screening is to identify breast cancer at
a stage when a surgical cure is likely. Traditionally this
includes  small  breast  cancers  (<1  cm)  that  are
node-negative and with no evidence of distant spread.
For these women cure can be expected in over 90% of
cases. But BRCA1-associated breast cancers are typically
high-grade and oestrogen-receptor negative [5] and so
prognosis might be worse than average [6, 7]. The
majority of physicians will offer adjuvant chemotherapy
to women with cancer of this type to boost the cure rate
beyond that offered by surgery alone. But there is another
problem. Among BRCA1 carriers we see little correlation
between tumour size and lymph-node positivity [8]. About
one-third of BRCA1 carriers will have lymph node
metastases detected at diagnosis, regardless of tumour
size (as tumours are being diagnosed at progressively
smaller sizes through MRI etc., this may no longer be the
case). Therefore it is problematic to predict the benefits
of  screening  using  survival  data  generated  from
a comparison group of non-carriers. 
Currently, screening is done with mammography or
with MRI. Although MRI appears to be superior to
mammography in early studies [9, 10], access to MRI is
rare outside of research settings. The test is costly and
time-consuming  both  for  the  patient  and  for  the
radiologist. Unfortunately mammography does not seem
to be a useful alternative to MRI and the exposure to
radiation with mammography is worrisome. We have no
direct data that ionizing radiation is a carcinogen for
BRCA carriers; the data on this topic is derived from
cohort studies of Hiroshima survivors and from young
women treated for Hodgkin’s disease. In both groups
younger women were at particularly high risk. It is striking
that early menopause mitigated against the carcinogenic
effect of therapeutic radiation in women undergoing
treatment for Hodgkin’s disease [11]. Surgical menopause
is also highly effective in preventing BRCA1-related breast
cancers [12-14]. The parallels between radiation-induced
carcinogenesis and BRCA1-associated carcinogenesis
are notable; however, this should not be surprising given
that a primary function of BRCA1 is to help in the repair
of double strand DNA breaks and these are typical of the
type induced by ionizing radiation. It is likely that both
radiation-induced and BRCA1-associated breast cancers
are initiated by chromosome breakage. Both appear to
be  advanced  by  later  ovarian  hormone  exposure.
Therefore we might expect other cofactors to be in
common and the tumour types to be similar. The incidence
of breast cancer in BRCA1 carriers rises from the age of
25 until menopause, after which it plateaus. At the age
of 25 radiation (even in small doses) is worrisome. 
Currently mammography is almost universally
recommended to BRCA1 and BRCA2 carriers. This
recommendation is largely based on historical grounds,
out  of  fear  of  litigation,  and  wishful  thinking.
Mammography has not been shown to be effective in
reducing mortality from high-grade breast cancers in
young women. After 13 years of follow-up there was
no  reduction  in  mortality  from  breast  cancer  in
Canadian  women  aged  40-49  randomized  to
mammography versus usual care [15]. 105 deaths
occurred in the mammography group and 108 deaths
occurred in the unscreened group. In the Swedish
two-county trial (which is widely cited by mammography
advocates as providing the best evidence in favour)
there was no reduction in death from high-grade breast
cancers in women aged under 50 [16]. Goffin and
colleagues found that only two of eight breast cancers
of  less  than  2 centimetres  were  detectable  by
mammogram in BRCA1 carriers aged under 50 at
diagnosis, versus 27 of 35 from non-carrier controls
(p=0.01) [17]. Brekelmans et al followed women at
high risk for breast cancer with annual mammography
and found that the BRCA carriers were more likely to
present with an interval cancer, or with an advanced
disease, than a comparable group of non-carriers [18]. 
MRI appears to be much more effective than
mammography in detecting early hereditary breast
cancers. In my opinion, breast cancer screening should
consist of annual MRI from the age of 25. Also,
a bilateral MRI should be conducted in a BRCA carrier
with a newly diagnosed breast cancer to assess the
extent of disease, in particular if breast-conserving
surgery is to be considered. 
To date the general approach to prevention of
hereditary breast cancer has been anti-hormonal.
Although the underlying defect conferred by a BRCA1
mutation is the inability to proficiently repair double
strand DNA breaks, prevention has not been aimed at
correcting this deficit but rather at reducing the effect of
promoting factors. To date the established cofactors for
BRCA1-associated breast cancers are hormonally-based
[19]. Anti-hormonal approaches include tamoxifen,
raloxifene  and  other  SERMS,  ovarian  ablation
(oophorectomy, radiation or chemical ablation) and
aromatase inhibition. Of these, only tamoxifen andH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 7
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oophorectomy have been well studied in the context of
BRCA1 and BRCA2 mutations. The rationale for the
anti-hormonal approach comes from the observation that
oophorectomy prevents against breast cancer in BRCA1
and BRCA2 carriers [12-14]. Cohort studies estimated
the reduction in breast cancer risk associated with
a pre-menopausal oophorectomy to be about 50%. We
are currently analysing a large case-control study of over
1000 cases of hereditary breast cancer and an equal
number of matched controls to determine the optimal
age of oophorectomy and the duration of protection. 
If one anti-hormonal approach is effective, why not
all? There is little empirical data on the degree of
protection against breast cancer offered by other forms
of ovarian ablation (radiation, GNRH agonists). A GNRH
agonist may be preferred by a woman who wishes to
preserve fertility, but the use of these drugs in BRCA
carriers is not yet widespread. Also, there is some concern
about the ability of these non-surgical approaches to
ovarian ablation to prevent tubal or ovarian cancer. 
On theoretical grounds tamoxifen should not reduce
the incidence of estrogen-receptor negative breast
cancers and most breast cancers which occur in BRCA1
carriers are oestrogen-receptor negative. The NSABP P1
trial attempted to address this issue, but only eight
BRCA1 carriers with breast cancer were identified in the
follow-up period [20]. Although no protective effect was
seen with tamoxifen this number is far too small for the
study to be informative. In a large case-control study
we found that tamoxifen reduced the incidence of
contralateral breast cancer in BRCA1 and BRCA2
carriers by about one-half [21]. To the extent that
contralateral cancers in carriers are representative of
all new primary breast cancers, the results of this study
could be extrapolated to the prevention of first primary
breast cancers. But this conclusion might be invalid if
the two primary cancers were not independent; for
example if tamoxifen was only given to ER-positive
patients and if the ER status of bilateral cancers were
completely correlated, then results of the case-control
study would confirm a protective effect of tamoxifen only
against ER-positive breast cancers. 
Few physicians are now prescribing tamoxifen to
BRCA carriers in the preventive setting [22]. We have
recently completed a survey of 100 unaffected BRCA
carriers one year after they learned of their mutation
status. Most women had undergone oophorectomy (60%)
and the side effects of oophorectomy were considered to
be acceptable by most. In contrast, 25% had undergone
a prophylactic mastectomy and only 10% of the women
had ever taken tamoxifen. Many women feared the side
effects of tamoxifen sufficiently to avoid the drug. Almost
as many women had taken raloxifene; it seems that the
presence of, or fear of, reduced bone density was a strong
enough incentive for many women to initiate a SERM and
most believed raloxifene to have fewer side effects than
tamoxifen. It is appealing to offer raloxifene to a BRCA
carrier after oophorectomy to protect against the effect
of surgical menopause on bone density and to reduce
the risk of breast cancer beyond oophorectomy alone,
but as yet there is no data on the effectiveness of
raloxifene on reducing the incidence of breast cancer in
this high risk group. 
It is too early to say if the combination of a SERM
and oophorectomy offers greater protection against
that of oophorectomy alone. However, it is striking
that  in  our  recent  study  the  combination  of
oophorectomy and tamoxifen reduced the incidence
of  contralateral  breast  cancer  by  82%  among
premenopausal women [4]. And most of these women
had ER-negative tumours. 
It is not practical to try to avoid the use of hormonal
replacement therapy completely by young women after
oophorectomy. There is no study yet which directly
addresses this question. However, it is probably best to
use hormone replacement sparingly, to attempt to treat
the specific symptom of menopause with the appropriate
drug and to consider a non-hormonal alternative when
possible. Oestrogen use should be limited to five years
if possible and progesterone avoided altogether (for this
reason it may be prudent to offer hysterectomy with
oophorectomy). In any case it is critical that the fallopian
tubes be removed at the time of oophorectomy because
a large  proportion  (probably  most)  gynaecologic
cancers in BRCA1 carriers actually arise in the tubes. If
a young woman is given oestrogen therapy post-
oophorectomy she may benefit from the addition of an
aromatase inhibitor. The purpose of the aromatase
inhibitor is to prevent the production of local oestrogen
in the breast and thereby minimise the concentration of
breast oestrogen. On the other hand, the aromatase
inhibitor should not eliminate the beneficial effects of
the  exogenous  oestrogen  on  reducing  the  acute
symptoms of menopause. 
Is it possible to counteract the effect of a BRCA1 or
BRCA2 mutation on the propensity for DNA damage?
Experiments may be done on animal models, on cell
cultures or using biological markers in vivo but there is
little data yet in this regard. Candidates for chemotherapy
include anti-oxidants. In general, anti-oxidants have notH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2004; 2(1) 8
been shown to be effective for preventing breast cancer,
but this may not be equally true for BRCA carriers, for
whom DNA damage appears to play an initiating role.
Oxidative damage appears to be an important factor in
prostate cancer aetiology (more so than in breast cancer)
and observational studies of selenium and lycopene in
prostate cancer prevention have been encouraging [23,
24]. There is little data yet to support the recommendation
of anti-oxidants to BRCA1 and BRCA2 carriers, but on
the other hand anti-oxidants are considered to be part
of what is considered a healthy diet and there are few
side effects. Currently I recommended a diet rich in
cruciferous vegetables and green tea, supplemented by
selenium and lycopene. 
What about preventive radiotherapy? In women with
breast cancer and a BRCA mutation and who have
undergone breast-conserving surgery and radiotherapy,
the risk of ipsilateral recurrence at ten years is about
10% [4]. This risk is actually far lower than the risk of
contralateral breast cancer in the same patients, which
is closer to 40% at ten years [4]. The ipsilateral events
include both local recurrences and new ipsilateral
primaries, whereas the contralateral cancers are believed
to be new primaries only. The effect of radiotherapy is
sufficiently strong that it must have an effect on reducing
the risk of second ipsilateral primaries as well as local
recurrences. One must expect therefore that a similar
dose of therapeutic radiation to the contralateral breast
would also reduce the risk of new cancer from 40% to
10% or lower. The long-term effect of radiation in these
patients is not known but studies to date of atomic bomb
survivors and Hodgkin’s disease survivors indicate that
radiotherapy is a breast carcinogen only when exposure
is early and when ovarian function is intact. Preventive
contralateral radiotherapy may prove to be beneficial
to patients over 40 who wish to conserve their breasts
and who undergo ovarian ablation (it is intriguing to
think that radiation may be a hazard at low doses but
that a high dose may have a protective effect). 
The risk of ovarian cancer is also elevated in BRCA1
carriers and when we consider a preventive strategy for
breast cancer we must consider the potential impact on
ovarian cancer risk, and vice versa. Current strategies
for ovarian cancer prevention include oophorectomy
[12-14], tubal ligation [25] and oral contraceptives 
[25, 26]. Two studies have looked at prophylactic
oophorectomy and ovarian cancer risk. The first of these
was purely prospective but the study population was so
small that in order to achieve a significant effect the breast
and ovarian cancer endpoints had to be combined [14].
The second study was larger but was based on historical
data [13]. The reduction effect of oophorectomy on
ovarian cancer risk was large, but it was not clear that
affected and unaffected carriers were equally likely to
have been ascertained in this study. A large prospective
cohort study will be required to resolve this question. It
would be ironic if ultimately the protective effect of
oophorectomy were found to be greater on breast cancer
reduction that on ovarian cancer reduction. 
There are two reasons why oophorectomy might
fail. Either a latent ovarian or tubal cancer may have
spread at the time surgery was performed or a primary
cancer  may  have  developed  in  the  peritoneum
post-surgery. If failure is due to the presence of a latent
cancer then the solution might be earlier surgery. The
second scenario is more problematic – we know of no
means to prevent primary peritoneal cancer and there
is no reason to believe that screening would be
effective here. It is important that we study the effects
of oral contraceptives, tubal ligation and hormone
replacement therapy on peritoneal cancer risk. 
In my opinion, the cornerstone for ovarian cancer
prevention in BRCA1 and BRCA2 carriers should be
oral contraceptives. If taken from the age of 30 to
35 oral contraceptives will reduce the risk of invasive
ovarian cancer thereafter by about 60% and will not
increase the risk of breast cancer [27]. And there are
few side effects. It is probably best to avoid oral
contraceptive use before the age of 25. Nor should
we ignore the protective effect offered by tubal
ligation just because we cannot explain how it works.
We observed a 63% reduction in ovarian cancer risk
with tubal ligation alone, and in combination with
oral contraceptives the risk reduction reached 72%.
For women who wish to defer oophorectomy beyond
the  age  of  35  or  for  those  who  have  finished
childbearing tubal ligation is a reasonable temporary
measure but should be followed by an oophorectomy
at a later date. 
Is there any additional benefit to be achieved by
ovarian cancer screening? Probably not. In our evaluation
of ten years of ovarian cancer screening at the Gilda
Radner Center at Cedars-Sinai in Los Angeles, the
majority  of  the  incident  cancers  appeared  to  be
peritoneal, most were detected at stage 3 and few of the
screening tests were positive at diagnosis [28]. In studies
of incidental tubal and ovarian cancers discovered at
prophylactic oophorectomy in asymptomatic women the
majority were discovered at stage 3 or 4. This observation
implies that an ovarian cancer passes through stage
1 and 2 quickly and that most of the pre-symptomatic
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phase is spent at stage 3. It is therefore improbable that
annual screening will be found to be effective. 
In summary, I believe that there is much that can
be done to reduce the risk of cancer in BRCA1 and
BRCA2 carriers. Currently I recommend breast MRI
annually from the age of 25, an oral contraceptive
from  the  age  of  30  to  35,  followed  by  an
oophorectomy at the age of 35. Hormone replacement
therapy should be transient and oestrogen-based and
targeted  towards  individual  acute  symptoms.  If
oophorectomy  is  postponed  then  women  should
consider a tubal ligation as a temporary measure to
protect against ovarian cancer. If women wish to
undergo a prophylactic mastectomy then no additional
measures for breast cancer prevention or screening are
recommended. For women who retain their breasts the
use of tamoxifen, raloxifene or an aromatase inhibitor
(post-oophorectomy) should be encouraged. 
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